Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond

Frontiers in Pharmacology

Volumn 4 JAN, Issue , 2014, Pages

  Davidson, David ^a   Amrein, Lilian ^a   Panasci, Lawrence ^a   Aloyz, Raquel ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

DNA damage; DNA repair; DNA PK inhibitors; DNA PK ; DNA PKcs

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMSACRINE; CAMPTOTHECIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; DNA DEPENDENT PROTEIN KINASE; DNA DEPENDENT PROTEIN KINASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FIRTECAN; IC 486241; IC 86621; IC 87102; IC 87361; IDARUBICIN; IMETELSTAT; IRINOTECAN; MITOXANTRONE; NK 314; NU 7026; NU 7441; OK 1035; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; RAD51 PROTEIN; SU 11752; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLIN; WORTMANNIN;

BINDING SITE; COLON CANCER; CONCENTRATION RESPONSE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; NONHUMAN; REVIEW;

EID: 84881498136     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00005     Document Type: Review

References (65)

1. Allen, C., Halbrook, J., and Nickoloff, J. A. (2003). Interactive competition between homologous recombination and non-homologous end joining. Mol. Cancer Res. 1, 913-920
2. Amrein, L., Davidson, D., Shawi, M., Petruccelli, L. A., Miller, W. H. Jr., Aloyz, R., et al. (2011). Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy. Leuk. Res. 35, 1080-1086
3. An, J., Huang, Y.-C., Xu, Q.-Z., Zhou, L.-J., Shang, Z.-F., Huang, B., et al. (2010). DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progression. BMC Mol. Biol. 11:18. doi:10.1186/1471-2199-11-18
4. Azad, A., Jackson, S., Cullinane, C., Natoli, A., Neilsen, P. M., Callen, D. F., et al. (2011). Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol. Cancer Res. 9, 1696-1707
5. Bennardo, N., Cheng, A., Huang, N., and Stark, J. M. (2008). Alternative-nhej is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 4:e1000110. doi:10.1371/journal.pgen.1000110
6. Burma, S., Chen, B. P. C., and Chen, D. J. (2006). Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst.) 5, 1042-1048
7. Callen, E., Jankovic, M., Wong, N., Zha, S., Chen, H.-T., Difilippantonio, S., et al. (2009). Essential role for DNA-PKcs in DNA double-strand break repair and apoptosis in ATM-deficient lymphocytes. Mol. Cell 34, 285-297
8. Cardinale, A., and Biocca, S. (2008). The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends. Mol. Med. 14, 373-380
9. Cardoso, F., Bedard, P. L., Winer, E. P., Pagani, O., Senkus-Konefka, E., Fallowfield, L. J., et al. (2009). International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J. Natl. Cancer Inst. 101, 1174-1181
10. Chen, B. P. C., Chan, D. W., Kabayashi, J., Burma, S., Asaithamby, A., Morotomi-Yano, K., et al. (2005). Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J. Biol. Chem. 280, 14709-14715
11. Clapham, K. M., Bardos, J., Finlay, M. R. V., Golding, B. T., Griffen, E. J., Griffin, R. J., et al. (2011). DNA-dependent protein kinase (DNA-PK) inhibitors: Structure-activity relationships for o-alkoxyphenylchromen-4-one probes of the ATP-binding domain. Bioorg. Med. Chem. Lett. 21, 966-970
12. Collis, S. J., DeWeese, T. L., Jeggo, P. A., and Parker, A. R. (2005). The life and death of DNA-PK. Oncogene 24, 949-961
13. Davidson, D., Coulombe, Y., Martinez-Marignac, V., Amrein, L., Grenier, J., Hodkinson, K., et al. (2012a). Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest. New Drugs 30, 1248-1256
14. Davidson, D., Grenier, J., Martinez-Marignac, V., Amrein, L., Shawi, M., Tokars, M., et al. (2012b). Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest. New Drugs 30, 1736-1742.
15. Davis, A. J., So, S., and Chen, D. J. (2010). Dynamics of the PI3K-like protein kinase members ATM and DNA-PKcs at DNA double strand breaks. Cell Cycle 9, 2527-2534
16. Dobbs, T. A., Tainer, J. A., and Lees-Miller, S. P. (2010). A structural model for regulation of nhej by DNA-PKcs autophosphorylation. DNA Repair (Amst.) 9, 1307-1314
17. Durant, S., and Karran, P. (2003). Vanillins, a novel family of DNAPK inhibitors. Nucleic Acids Res. 31, 5501-5512
18. Durocher, D., and Jackson, P. J. (2001). DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr. Opin. Cell Biol. 13, 225-231
19. Fuhrman, C. B., Kilgore, J., LaCoursiere, Y. D., Lee, C. M., Milash, B. A., Soisson, A. P., et al. (2008). Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol. Oncol. 110, 93-98
20. Hisatomi, T., Sueoka-Aragane, N., Sato, A., Tomimasu, R., Ide, M., Kurimasa, A., et al. (2011). NK314 potentiates anti-tumor activity with adult t-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II and DNA-dependent protein kinase. Blood 117, 3575-3584
21. Hollick, J. J., Golding, B. T., Hardcastle, I. R., Martin, N., Richardson, C., Rigoreau, L. J. M., et al. (2003). 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK). Bioorg. Med. Chem. Lett. 13, 3083-3086
22. Ihmaid, S., Al-Rawi, J., Bradley, C., Angove, M. J., Robertson, M. N., and Clark, R. L. (2011). Synthesis, structural elucidation, DNA-PK inhibition, homology modelling and anti-platelet activity of morpholino-substituted-1,3-naphth-oxazines. Bioorg. Med. Chem. 19, 3983-3994
23. Ihmaid, S. K., Al-Rawi, J. M., Bradley, C. J., Angove, M. J., and Robertson, M. N. (2012). Synthesis, DNA-PK inhibition, anti-platelet activity studies of 2-(N-substituted-3-aminopyridine)-substituted-1,3-benzoxazines and DNA-PK and PI3K inhibition, homology modelling studies of 2-morpholino-(7,8-di and 8-substituted)-1,3-benzoxazines. Eur. J. Med. Chem. 5, 85-101
24. Johnson, R. D., and Jasin, M. (2001). Double-strand-break-induced homologous recombination in mammalian cells. Biochem. Soc. Trans. 29, 196-201
25. Kao, J., Rosenstein, B. S., Peters, S., Milano, M. T., and Kron, S. J. (2005). Cellular response to DNA damage. Ann. N. Y. Acad. Sci. 1066, 243-258
26. Kashishian, A., Douangpanya, H., Clark, D., Schlachter, S. T., Eary, C. T., Schiro, J. G., et al. (2003). DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol. Cancer Ther. 2, 1257-1264
27. Koike, M., Sugasawa, J., Yasuda, M., and Koike, A. (2008). Tissue-specific DNA-PK-dependent H2AX phosphorylation and y-H2AX elimination after x-irradiation in vivo. Biochem. Biophys. Res. Commun. 376, 52-55
28. Kong, X., Shen, Y., Jiang, N., Fei, X., and Mi, J. (2011). Emerging roles of DNA-PK besides DNA repair. Cell. Signal. 23, 1273-1280
29. Kuo, C. C., Liu, J. F., and Chang, J. Y. (2006). DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J. Pharmacol. Exp. Ther. 316, 946-954
30. Lieber, M. R. (2008). The mechanism of human nonhomologous DNA end joining. J. Biol. Chem. 283, 1-5
31. Lieber, M. R., Yu, K., and Raghavan, S. C. (2006). Roles of nonhomologous DNA end joining, v(d)j recombination, and class switch recombination in chromosomal translocations. DNA Repair (Amst.) 5, 1234-1245
32. Ma, Y., Pannicke, U., Schwarz, K., and Lieber, M. R. (2002). Hairpin opening and overhang processing by an artemis/DNA-dependent protein kinase complex in nonhomologous end joining and v(d)j recombination. Cell 108, 781-794
33. Mansour, W. Y., Schumacher, S., Rosskopf, R., Rhein, T., Schmidt-Petersen, F., Gatzemeier, F., et al. (2008). Hierarchy of nonhomologous end-joining, single-strand annealing and gene conversion at site-directed DNA double-strand breaks. Nucleic Acids Res. 36, 4088-4098
34. Morris, E. P., Rivera-Calzada, A., da Fonseca, P. C. A., Llorca, O., Pearl, L. H., and Spagnolo, L. (2011). Evidence for a remodelling of DNA-PK upon autophosphorylation from electron microscopy studies. Nucleic Acids Res. 39, 5757-5767
35. Mukherjee, B., Kessinger, C., Kobayashi, J., Chen, B., Chen, D., Chatterjee, A., et al. (2006). DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair (Amst.) 5, 575-590
36. Neal, J. A., Dang, V., Douglas, P., Wold, M. S., Lees-Miller, S. P., and Meek, K. (2011). Inhibition of homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable, and is modulated by autophosphorylation. Mol. Cell. Biol. 31, 1719-1733
37. Neal, J. A., and Meek, K. (2011). Choosing the right path: does DNA-PK help make the decision? Mutat. Res. 711, 73-86
38. Nutley, B. P., Smith, N. F., Hayes, A., Kelland, L. R., Brunton, L., Golding, B. T., et al. (2005). Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br. J. Cancer 93, 1011-1018
39. Peddi, P., Loftin, C. W., Dickey, J. S., Hair, J. M., Burns, K. J., Aziz, K., et al. (2010). DNA-PKcs deficiency leads to persistence of oxidatively induced clustered DNA lesions in human tumor cells. Free Radic. Biol. Med. 48, 1435-1443
40. Raftery, L., and Goldberg, R. M. (2010). Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J. 16, 214-219
41. Reitsema, T., Klokov, D., Banath, J., and Olive, P. (2005). DNA-PK is responsible for enhanced phosphorylation of histone H2AX under hypertonic conditions. DNA Repair (Amst.) 4, 1172-1181
42. Rudolf, E., Rudolf, K., and Cervinka, M. (2011). Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells. Apoptosis 16, 1165-1176
43. Sauveur-Michel, M., Stauffer, F., Schnell, C., and Garcia-Echeverria, C. (2009). PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans. 37, 265-272
44. Scott, A. M. (2012). Antibody therapy of cancer. Nat. Rev. Cancer 12, 278-287
45. Seymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., et al. (2007). Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (mrc focus): a randomised controlled trial. Lancet 370, 143
46. Shawi, M., Amrein, L., Gryaznov, S. M., Autexier, C., and Aloyz, R. (2011). Telomerase inhibition affects fludaribine sensitivity in chronic lymphocytic leukemia lymphocytes. Eur. J. Cancer 47, S640-S641
47. Shinohara, E. T., Geng, L., Tan, J., Chen, H., Shir, Y., Edwards, E., et al. (2005). DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res. 65, 4987-4992
48. Sibanda, B. L., Chirgadze, D. Y., and Blundell, T. L. (2010). Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of heat repeats. Nature 463, 118-121
49. Soubeyrand, S., Pope, L., Pakuts, B., and Hache, J. G. (2003). Threonines 2638/2647 in DNA-PK are essential for cellular resistance to ionizing radiation. Cancer Res. 63, 1198-1201
50. Stiff, T., O'Driscoll, M., Rief, N., Iwabuchi, K., Lobrich, M., and Jeggo, P. (2004). ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 64, 2390-2396
51. Stronack, E. A., Chen, M., Maginn, E. N., Agarwai, R., Mills, G. B., Harpreet, W., et al. (2011). DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 13, 1069-1080
52. Sung, P., and Klein, H. (2006). Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat. Rev. Mol. Cell Biol. 7, 739-750
53. Take, Y., Kumano, M., Hirobumi, T., Nishimura, S., and Okuyama, A. (1996). DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT-116 cells containing wild-type p53 induced by adriamycin. Biochem. Biophys. Res. Commun. 221, 207-212
54. Tavecchio, M., Munck, J., Cano, C., Newell, D., and Curtin, N. (2012). Further characterisation of the cellular activity of the DNA-pk inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother. Pharmacol. 69, 155-164.
55. Thompson, L. H. (2012). Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat. Res. 751, 158-246
56. Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., et al. (2009). Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572
57. Uematsu, N., Weterings, E., Morotomi-Yano, K., Jakob, B., Taucher-Scholz, G., Mari, P.-O., et al. (2007). Autophosphorylation of DNA-PKcs regulates its dynamics at DNA double-strand breaks. J. Cell Biol. 177, 219-229
58. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one (ly294002). J. Biol. Chem. 269, 5241-5248
59. Wang, H., Wang, M., Bocker, W., and Iliakis, G. (2005). Complex H2AX phosphorylation patterns by multiple kinases including ATM and DNA-PK in human cells exposed to ionizing radiation and treated with kinase inhibitors. J. Cell. Physiol. 202, 492-502
60. Wei, S., Xiong, M., Zhan, D.-Q., Liang, B.-Y., Wang, Y.-Y., Gutmann, D. H., et al. (2012). Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing s-phase arrest through a p53-dependent pathway. Carcinogenesis 33, 538-547
61. Willmore, E., de Caux, S., Sunter, N. J., Tilby, M. J., Jackson, G. H., Austin, C. A., et al. (2004). A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103, 4659-4665
62. Xiong, H., Lee, R. J., Haura, E. B., Edwards, J. G., Dynan, W. S., and Shuyi, L. (2011). Intranuclear delivery of a novel antibody-derived radiosensitizer targeting the DNA-dependent protein kinase catalytic subunit. Int. J. Radiat. Oncol. Biol. Phys. 83, 1023-1030
63. Yang, C., Betti, C., Singh, S., Toor, A., and Vaughan, A. (2009). Impaired NHEJ function in multiple myeloma. Mutat. Res. 660, 66-73
64. Yang, J., Yingnian, Y., Hamrick, H. E., and Duerksen-Hughes, J. (2003). ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 24, 1571-1580
65. Zhao, Y., Thomas, H. D., Batey, M. A., Cowell, I. G., Richardson, C. J., Griffin, R. J., et al. (2006). Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 66, 5354-5362